Van ECK Associates Corp Cuts Stock Holdings in Elanco Animal Health Incorporated $ELAN

Van ECK Associates Corp reduced its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 9.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 798,456 shares of the company’s stock after selling 78,736 shares during the period. Van ECK Associates Corp owned approximately 0.16% of Elanco Animal Health worth $16,081,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of ELAN. AlphaQuest LLC boosted its holdings in shares of Elanco Animal Health by 13.7% during the 3rd quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock valued at $120,000 after purchasing an additional 718 shares during the last quarter. Jones Financial Companies Lllp increased its holdings in shares of Elanco Animal Health by 15.2% in the third quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock worth $119,000 after purchasing an additional 798 shares during the last quarter. MTM Investment Management LLC lifted its position in shares of Elanco Animal Health by 5.5% in the second quarter. MTM Investment Management LLC now owns 15,268 shares of the company’s stock worth $218,000 after buying an additional 800 shares in the last quarter. US Bancorp DE lifted its position in shares of Elanco Animal Health by 1.9% in the third quarter. US Bancorp DE now owns 43,810 shares of the company’s stock worth $882,000 after buying an additional 824 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. boosted its stake in Elanco Animal Health by 80.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after buying an additional 900 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ELAN. Argus upgraded Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a report on Wednesday, November 19th. Barclays began coverage on shares of Elanco Animal Health in a report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 target price for the company. JPMorgan Chase & Co. boosted their price target on shares of Elanco Animal Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, February 19th. KeyCorp upped their price target on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Finally, Morgan Stanley lifted their price objective on shares of Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and an average price target of $27.67.

Elanco Animal Health Trading Down 0.2%

Shares of NYSE:ELAN traded down $0.05 during trading on Friday, hitting $22.63. The company had a trading volume of 382,931 shares, compared to its average volume of 4,487,930. The stock has a market cap of $11.25 billion, a price-to-earnings ratio of -47.17, a price-to-earnings-growth ratio of 2.99 and a beta of 1.83. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.08. The company has a fifty day simple moving average of $24.51 and a two-hundred day simple moving average of $22.15. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $27.72.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 EPS. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.